Petrelintide
Amylin · s.c. · Zealand / Roche
Summary
- Also known as
- ZP8396
- Mechanism
- Amylin
- Route
- s.c.
- Company
- Zealand / Roche
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3 ZUPREME programme (ZUPREME-3, -4, -5) initiated with Roche; phase 2 ZUPREME-1 published (Lancet Diabetes Endocrinol 2026), ZUPREME-2 topline in T2D (Oct 2026) verify
- Next milestone
- Phase 3 readouts
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 2 phase 3 ongoing | Phase 3 ongoing | |
| T2D | 2 phase 3 ongoing | Phase 3 ongoing | |
| CV outcomes | 2 phase 3 ongoing | Phase 3 ongoing | |
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZUPREME-1 | petrelintide 1.0 mg | obesity | 28 | — | −7.9 % vs −1.7 % Δ −6.2 pp | — | — | 5.0 vs 5.0 | 16.5 vs 24.7 | 19.0 vs 6.0 | 4.0 vs 6.0 | 3.0 vs 4.0 | — | verified |
| ZUPREME-1 | petrelintide 2.5 mg | obesity | 28 | — | −7.9 % vs −1.7 % Δ −6.2 pp | — | — | 1.0 vs 5.0 | 11.1 vs 24.7 | 12.0 vs 6.0 | 0.0 vs 6.0 | 1.0 vs 4.0 | — | verified |
| ZUPREME-1 | petrelintide 5.0 mg | obesity | 28 | — | −9.8 % vs −1.7 % Δ −8.1 pp | — | — | 5.0 vs 5.0 | 9.6 vs 24.7 | 23.0 vs 6.0 | 0.0 vs 6.0 | 6.0 vs 4.0 | — | verified |
| ZUPREME-1 | petrelintide 7.0 mg | obesity | 28 | — | −9.3 % vs −1.7 % Δ −7.6 pp | — | — | 1.0 vs 5.0 | 12.7 vs 24.7 | 15.0 vs 6.0 | 3.0 vs 6.0 | 4.0 vs 4.0 | — | verified |
| ZUPREME-1 | petrelintide 9.0 mg | obesity | 28 | — | −9.4 % vs −1.7 % Δ −7.7 pp | — | — | 10.0 vs 5.0 | 18.3 vs 24.7 | 28.0 vs 6.0 | 9.0 vs 6.0 | 4.0 vs 4.0 | — | verified |
| ZUPREME-2 (obesity + T2D) | petrelintide, highest dose | t2d | 28 | — | −9.2 % vs −2.0 % Δ −7.2 pp | — | −0.7 vs +0.2 | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- petrelintide 1.0 mg: Weight at week 28 (primary end point, efficacy estimand); HbA1c, SBP and safety at week 42 (end of treatment). Week-42 treatment-policy weight is given only in a figure.
- petrelintide 2.5 mg: Weight at week 28 (primary end point, efficacy estimand); HbA1c, SBP and safety at week 42 (end of treatment). Week-42 treatment-policy weight is given only in a figure.
- petrelintide 5.0 mg: Weight at week 28 (primary end point, efficacy estimand); HbA1c, SBP and safety at week 42 (end of treatment). Week-42 treatment-policy weight is given only in a figure.
- petrelintide 7.0 mg: Weight at week 28 (primary end point, efficacy estimand); HbA1c, SBP and safety at week 42 (end of treatment). Week-42 treatment-policy weight is given only in a figure.
- petrelintide 9.0 mg: Weight at week 28 (primary end point, efficacy estimand); HbA1c, SBP and safety at week 42 (end of treatment). Week-42 treatment-policy weight is given only in a figure.
- petrelintide, highest dose: Topline release: best of three dose arms ("up to"); doses and per-arm results not yet disclosed.
Verbatim quotes from the source (32)
- petrelintide 1.0 mg · weight_eff · Abstract; Table 2
−7·9% (95% CI −9·0 to −6·7) with petrelintide 1·0 mg
- petrelintide 1.0 mg · ae_dc · Table 3
Adverse events leading to discontinuation of treatment* 4 (5%) 1 (1%) 4 (5%) 1 (1%) 8 (10%) 16 (4%) 4 (5%)
- petrelintide 1.0 mg · nausea · Table 3
Nausea 15 (19%) 10 (12%) 19 (23%) 12 (15%) 23 (28%) 79 (20%) 5 (6%)
- petrelintide 1.0 mg · vomiting · Table 3
Vomiting 3 (4%) 0 0 2 (3%) 7 (9%) 12 (3%) 5 (6%)
- petrelintide 1.0 mg · sae · Table 3
Serious adverse events 2 (3%) 1 (1%) 5 (6%) 3 (4%) 3 (4%) 14 (3%) 3 (4%)
- petrelintide 1.0 mg · disc_any · Figure 1 (trial profile)
13 discontinued treatment 4 adverse events
- petrelintide 2.5 mg · weight_eff · Abstract; Table 2
−7·9% (−9·0 to −6·7) with petrelintide 2·5 mg
- petrelintide 2.5 mg · ae_dc · Table 3
Adverse events leading to discontinuation of treatment* 4 (5%) 1 (1%) 4 (5%) 1 (1%) 8 (10%) 16 (4%) 4 (5%)
- petrelintide 2.5 mg · nausea · Table 3
Nausea 15 (19%) 10 (12%) 19 (23%) 12 (15%) 23 (28%) 79 (20%) 5 (6%)
- petrelintide 2.5 mg · vomiting · Table 3
Vomiting 3 (4%) 0 0 2 (3%) 7 (9%) 12 (3%) 5 (6%)
- petrelintide 2.5 mg · sae · Table 3
Serious adverse events 2 (3%) 1 (1%) 5 (6%) 3 (4%) 3 (4%) 14 (3%) 3 (4%)
- petrelintide 2.5 mg · disc_any · Figure 1 (trial profile)
9 discontinued treatment 4 lack of efficacy 4 other 1 adverse event
- petrelintide 5.0 mg · weight_eff · Abstract; Table 2
−9·8% (−10·9 to −8·6) with petrelintide 5·0 mg
- petrelintide 5.0 mg · ae_dc · Table 3
Adverse events leading to discontinuation of treatment* 4 (5%) 1 (1%) 4 (5%) 1 (1%) 8 (10%) 16 (4%) 4 (5%)
- petrelintide 5.0 mg · nausea · Table 3
Nausea 15 (19%) 10 (12%) 19 (23%) 12 (15%) 23 (28%) 79 (20%) 5 (6%)
- petrelintide 5.0 mg · vomiting · Table 3
Vomiting 3 (4%) 0 0 2 (3%) 7 (9%) 12 (3%) 5 (6%)
- petrelintide 5.0 mg · sae · Table 3
Serious adverse events 2 (3%) 1 (1%) 5 (6%) 3 (4%) 3 (4%) 14 (3%) 3 (4%)
- petrelintide 5.0 mg · disc_any · Figure 1 (trial profile)
8 discontinued treatment 4 adverse events
- petrelintide 7.0 mg · weight_eff · Abstract; Table 2
−9·3% (−10·5 to −8·2) with petrelintide 7·0 mg
- petrelintide 7.0 mg · ae_dc · Table 3
Adverse events leading to discontinuation of treatment* 4 (5%) 1 (1%) 4 (5%) 1 (1%) 8 (10%) 16 (4%) 4 (5%)
- petrelintide 7.0 mg · nausea · Table 3
Nausea 15 (19%) 10 (12%) 19 (23%) 12 (15%) 23 (28%) 79 (20%) 5 (6%)
- petrelintide 7.0 mg · vomiting · Table 3
Vomiting 3 (4%) 0 0 2 (3%) 7 (9%) 12 (3%) 5 (6%)
- petrelintide 7.0 mg · sae · Table 3
Serious adverse events 2 (3%) 1 (1%) 5 (6%) 3 (4%) 3 (4%) 14 (3%) 3 (4%)
- petrelintide 7.0 mg · disc_any · Figure 1 (trial profile)
10 discontinued treatment 7 other 1 adverse event
- petrelintide 9.0 mg · weight_eff · Abstract; Table 2
−9·4% (−10·5 to −8·3) with petrelintide 9·0 mg
- petrelintide 9.0 mg · ae_dc · Table 3
Adverse events leading to discontinuation of treatment* 4 (5%) 1 (1%) 4 (5%) 1 (1%) 8 (10%) 16 (4%) 4 (5%)
- petrelintide 9.0 mg · nausea · Table 3
Nausea 15 (19%) 10 (12%) 19 (23%) 12 (15%) 23 (28%) 79 (20%) 5 (6%)
- petrelintide 9.0 mg · vomiting · Results, paragraph 10; Table 3
The petrelintide 9·0 mg group was the only group in which the incidence of vomiting (seven [9%] of 82) exceeded that observed with placebo
- petrelintide 9.0 mg · sae · Table 3
Serious adverse events 2 (3%) 1 (1%) 5 (6%) 3 (4%) 3 (4%) 14 (3%) 3 (4%)
- petrelintide 9.0 mg · disc_any · Figure 1 (trial profile)
15 discontinued treatment 8 adverse events
- petrelintide, highest dose · weight_eff · company announcement
Petrelintide achieved up to 9.2% mean body weight reduction at week 28 versus 2.0% with placebo
- petrelintide, highest dose · hba1c · company announcement
At week 28, petrelintide demonstrated a HbA1c reduction of up to 0.65% versus an increase of 0.23% with placebo
Registered trials (4)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| ZUPREME-4 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes | Obesity | Phase 3 | recruiting | 2026-10 → 2028-10 | 600 | recruiting | NCT07843485 |
| ZUPREME-5 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease | Obesity | Phase 3 | recruiting | 2026-09 → 2030-07 | 2500 | recruiting | NCT07843472 |
| ZUPREME-3 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity | Obesity | Phase 3 | recruiting | 2026-09 → 2028-12 | 3900 | recruiting | NCT07843498 |
| NCT06951854 Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder | Other | Phase 2 | recruiting | 2025-04 → 2025-09 | 105 | recruiting | NCT06951854 |
Primary sources
- Garvey WT, Ard J, Connery L, Frias JP, le Roux CW, Pietiläinen KH, et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2026;14(11):914-926. PMID: 42810355.
- Zealand Pharma. Positive phase 2 ZUPREME-2 topline results for petrelintide [company announcement No. 54/2026]. 2026 Oct 7. Available from: https://view.news.eu.nasdaq.com/view?id=1468986
How to cite this page
Cite the primary publication for any single result; every value above links to it.